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Summary The effect of intraperitoneal (i.p.) injection of recombinant human interleukin-lp (rhIL-1p) was
studied in three i.p. nude mouse xenograft models of human ovarian cancer (HU, OS, and LA). Intra-
peritoneal rhIL-lp administration led to a dose dependent replacement of peritoneal ascitic tumour with solid
tumours attached to the peritoneum and intraabdominal viscera in two (HU and LA) out of the three
xenograft models. In the third xenograft model (OS), low doses of rhIL- p (10 ng day) promoted micrometa-
static peritoneal implants of tumour, but higher doses of rhIL-Ip (1 fig day) had a marked antitumour effect.
This was due to direct cytotoxicity for tumour cells and was not related to peritoneal neutrophil influx induced
by rhIL-1p. Recombinant human TNF (rhTNF) also promoted tumour implantation in all three xenograft
models, but its antitumour effects differed from rhIL-1p. TNF increased the survival of HU and LA bearing
mice, but had no antitumour effect in the OS xenograft model. Analysis of peritoneal fluid and tumour
xenografts showed that TNF induced murine IL-1 in the tumour bearing mice. The magnitude of IL-1
induction indicated that TNF induced IL-1 did not contribute significantly to its effects.
Interleukin-I (IL-1) and tumour necrosis factor (TNF) are
pleiotropic cytokines with overlapping biological activities
(Le & Vilcek, 1987; Dinarello, 1991). TNF has been exten-
sively studied in experimental murine tumour models and in
human cancer xenograft models (Palladino et al., 1987; Asher
et al., 1987; Haranaka et al., 1984; Balkwill et al., 1986). IL-1
has growth inhibitory effects on several human tumour cell
lines in vitro (Tsai & Gaffney, 1986; Ruggiero & Baglioni,
1987; Onozaki et al., 1985), and antitumour effects in murine
tumour models (Braunschweiger et al., 1988; Nakamura et
al., 1986; Berladelli et al., 1989), but has not been extensively
studied in human cancer xenograft models. Although TNF
has been shown to induce IL-1 in a variety of cell types in
vitro (Philip & Epstein, 1986; Elias et al., 1989), and in vivo
(Dinarello et al., 1986), there have been no reported studies
assessing the contribution of TNF-induced IL-1 to the effect
of TNF in experimental animal models to date.
In studies of the effects of rhTNF in intraperitoneal human
ovarian cancer xenograft models, i.p.rhTNF therapy pro-
longed the survival of mice bearing two of three human
ovarian cancer xenografts, but also enhanced the peritoneal
implantation of tumour cells (Malik et al., 1989). Other
studies suggested that TNF production by human ovarian
cancers may contribute to the biological behaviour of these
tumours in man (Malik et al., 1990; Naylor et al., 1990). IL-1
production by tumours may also contribute to tumour
pathophysiology, for example by inducing hypercalcaemia
(Sato et al., 1987) and promoting growth, adhesion and
metastasis of tumour cells (Giavazzi et al., 1990; Bani et al.,
1991; Gelin et al., 1991). The studies reported in this paper
show that IL-1, like TNF, can have pronounced antitumour
activity, but can also enhance the implantation of human
ovarian cancer cells in the peritoneal cavity. Although the
effects of TNF and IL-1 on tumour implantation were
similar, there was a notable difference in the susceptibility of




Six to 12 week old specific pathogen free female nu/nu (nude)
mice of mixed genetic background were maintained as de-
scribed previously (Balkwill et al., 1982). Ovarian cancer
xenografts OS, LA, and HU were established from primary
human tumours as described previously (Ward et al., 1987).
OS originated from a 51 year old woman with a moderately
differentiated serous cystadenocarcinoma, LA from a 72 year
old woman with a poorly differentiated mucinous cystadeno-
carcinoma, and HU from a 23 year old woman with a
moderately differentiated serous cystadenocarcinoma. OS was
used between passages 55 and 67, LA between passages 43
and 48, and HU between passages 35 and 56. Northern
analysis of xenograft mRNA for human TNF and human
IL-1 mRNA was negative. The survival time of tumour
bearing mice and biological behaviour of the tumour were
constant during this time. At the start of each experiment
mice were injected i.p. with 0.1 ml of ascitic tumour (approx-
imately 1 x 106 cells) diluted 1 + 1 in RPMI 1640 medium.
Therapy started 7 days later. The cytokines were admini-
stered intraperitoneally, i.p. for up to 3 weeks. Six to eight
mice were used in each group in experiments where survival
was evaluated, eight mice were used when tumour weights
were recorded, and three mice were used in each group for
the peritoneal cell anlayses. Statistical evaluation of survival
data was carried out by the Mann-Whitney U test, and the
peritoneal cell data was evaluated by Students paired t-test.
Cytokines
Recombinant human tumour necrosis factor (rhTNF), was
provided by BioGent, Gent, Belgium, and was more than
99% pure. Endotoxin levels were less than 0.2 ngmg' and
the specific activity was 2 x IO' units mg-'. Recombinant
interleukin-1p (rhIL-lp) was provided by the Sclavo Research
Center, Sclavo, Italy. Endotoxin levels were less than 0.2 ng
mg-' and the specific activity was 1 x 108 units mg-'. Both
cytokines were diluted in calcium and magnesium free phos-
phate buffered saline (PBSA) plus 3 mg ml bovine serum
albumin (Sigma, Dorset, United Kingdom) and stored in
single dose aliquots at - 70'C until required. Mice were given
0.1 ml injections of the cytokine or the same volume of
diluent i.p. Recombinant interleukin-2 (IL-2) (specific activity
3 x 106 units mg-1) was provided by Glaxo, Geneva.
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Analysis ofperitoneal cells
Mice were killed and immediately injected i.p. with 5 ml
PBSA and the abdomen gently massaged before withdrawing
approximately 5 ml of lavage fluid which was stored on ice.
Tumour clumps found in the ascites were allowed to sedi-
ment for 5 min at room temperature, and fixed in formol
saline. One hundred yil of peritoneal lavage fluid adjusted to
8 x I05 cellsml' was cytocentrifuged onto microscope slides
at 500 r.p.m. for 5 min using s Shandon Cytospin (Shandon,
Buckinghamshire, UK). Dried cytospins were initially stained
with Merz & Dade Diff-Quik (three solutions 1 min in each).
Two hundred cells were counted to give a percent neutrophil
result. At least 200 cells were counted on each slide. Solid
tumours found in the peritoneal cavity on post mortem were
fixed in formol saline.
Northern analysis
Ascitic xenografts, homogenised solid tumours, and cell lines
were lysed in 5 M guanidium isothiocynate buffer. Total
RNA was obtained after centrifugation through a gradient of
caesium chloride, and precipitated with 3 M sodium acetate
and ethanol according to the method of Chirgwin et al.
(1979). The RNA preparations were electrophoresed on a
1.4% agarose-formaldehyde gel containing 0.0002% ethidium
bromide. Fifteen tLg of RNA was loaded/lane, and electro-
phoresis carried out overnight at a voltage of 30 V. The gel
was photographed under UV light to ensure RNA integrity,
and capillary blotted onto nylon membrane (Biodyne A, Pall
Ultrafine Corp., Glen Cove, New York, USA). cDNA probes
were labelled with 32P-dCTP by random priming (Feinberg &
Vogelstein, 1984). Membranes were hybridised to the labelled
probes using a standard method (Church & Gilbert, 1984).
After high stringency washing, the membranes were exposed
to film (Kodak XAR5) for up to 7 days at - 70°C.
Probes
TNF, PstI fragment of p-hTNF 1 (Prof. W. Fiers, University
of Gent, Gent, Belgium): IL-la and IL-1p, pSPhIL-la.2 and
pSPhL-1p.2 (Dr. Alan Shaw, Glaxo Institute for Molecular
Biology, Geneva, Switzerland).
Biological assayfor interleukin-J
The assay used was as described by Gearing et al. (1987), and
is based on the IL-1 induced release of IL-2 from a murine
thymocyte cell line (NOB-1). The amount of IL-2 released is
assayed by measuring the IL-2 stimulated 3H-thymidine up-
take in an IL-2-dependent murine T cell line (CTLL). The
NOB-1 cells were grown in RPMI/5% FCS and the CTLL
cells in RPMI/10% FCS with 10 U/recombinant IL-2 (37°C,
5% CO2). Both cell lines were passaged every 2-3 days, by
splitting the total number of cells 1:10. For assay of IL-1
activity in the peritoneal cavity after injection of rhTNF,
three mice were killed by CO2 inhalation at various time
points after the injection of 1 ,ug rhTNF. The peritoneal
cavity was lavaged with cold RPMI, the lavage fluid centri-
fuged (1,500 r.p.m. for 5 min), and the supernatants col-
lected. The IL-1 activity of lavage fluid was assessed by
incubating 100 IlA with NOB cells (5 x I04 in 100til) for 24 h
(37C, 5% C02) in microtiter plates (Costar). The plates were
centrifuged (1,000 r.p.m. for 5 min), and 50,Ll of the super-
natant was incubated with CTLL cells (5 x 103 in 50gl) for
18-24 h (37°C, 5% CO2). One glCi 3H-thymidine (specific
activity 89 Ci mmol-': Amersham, Bucks., UK), was added
per well, and the plates harvested 4 h later. Incubation of
NOB cells with rhTNF (up to 1 gLgml-') did not give posi-
tive results in this assay. Incubation of CTLL cells with the
peritoneal washes did not lead to an increase in 3H-thymidine
incorporation.
In vitro assessment of3H-thymidine incorporation by tumour
cells
Ascitic tumours were suspended in RPMI, and depleted of
macrophages by incubating in tissue culture flasks at 37C
(5% CO2) for 2-4 h. The macrophages adhered to plastic,
and non-adherent tumour cells were harvested. Tumour cells
were made up into a 1/200 (v/v) suspension in RPMI/5%
FCS. One hundred flI of vigorously agitated tumour cell
suspension was added/well into 96 well microtiter plates
(Costar), and incubated for varying periods in a humidified
atmosphere at 37°C (5% CO2), with appropriate amount of
cytokine in a final volume of 200ft1. The wells were pulsed
with 1 yCi 3H-thymidine 4-24 h prior to harvesting (Titretek
Cell Harvester) and counting in an automated liquid scintilla-
tion counter (LKB model 1210).
Results
Effects ofIL-1p on survival ofnude mice bearing the OS, HU
and LA xenografts
Figures la, b and c show the effects of 3 weeks of therapy
with intraperitoneal therapy with rhIL-1I3 and rhTNF in the
three ovarian cancer xenograft models. The results were
collated from three separate experiments (eight mice per
treatment group in each experiment) with each xenograft.
RhIL-1l3 did not prolong the survival of mice bearing the
HU xenograft, whereas rhTNF led to significant prolonga-
tion of survival (P<0.005). In the LA xenograft model, a
marginal effect of rhIL-l,B on survival was noted (P<0.05),
but this was not as significant as that seen with daily i.p.
therapy with rhTNF (P<0.005). In the OS xenograft model,
rhIL-1p therapy led to marked improvement of survival
(P<0.005), whereas rhTNF did not have any significant
effects. Dose response studies in the OS xenograft model
showed that daily i.p. injections of rhIL-l,B at doses as low as
1 ng also significantly prolonged their survival compared to
diluent treated mice. In a typical experiment, 65% of mice
treated with 1 ng rhIL-l,/day were alive at 100 days, whereas
all the diluent treated mice had died with ascitic tumour by
25 days.
Effects ofIL-1lp and rhTNF on peritoneal cellpopulations
The comparative effects of rhTNF and rhIL-lp on PMN
influx were studied in the three xenograft models, 24 h after a
single injection of cytokines (Figure 2). The following con-
clusions could be drawn from the data:
(a) rhTNF and IL-1p significantly (P<0.05 to P<0.01)
increased the total PEC count in the three xenograft models
compared to diluent injected mice.
(b) Intraperitoneal injection of rhIL-lp led to a signi-
ficantly greater increase in the number of PECs at 24 h than
that induced by rhTNF in the OS and LA (but not HU)
bearing mice (P<0.05 and <0.005 respectively).
(c) The proportion of PMNs in rhIL-lp treated mice was
significantly greater than that in rhTNF treated mice (P<
0.005, <0.025, and <0.025 for the OS, HU and LA bearing
mice respectively).
(d) The total number of PMNs in rhIL-lp treated mice
was significantly greater than that in rhTNF treated mice
(P<0.005; <0.025 and <0.025 for the OS, HU and LA
bearing mice respectively).
(e) The increase in absolute numbers of PEC at 24 h was
solely due to an increase in the numbers of PMN.
(f) There was no apparent correlation between the PEC
changes induced by rhIL-lp and rhTNF and their effect on
survival in the three xenograft models.
The effects ofrhIL-1p on tumour cells in vitro
The cytostatic effects of rhIL-lp on the xenograft tumour
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Figure 1 Survival of nude mice bearing the a, HU, b, LA, and
the c, OS xenografts. = Diluent treated daily for 3 weeks i.p.
-* = rhTNF (1 ljg day) for 3 weeks i.p.; -0- = rhIL-1l
(1 lig day) for 3 weeks i.p.
tion by the tumour cells in short term in vitro culture (3
days), since none of the xenografts grew in long-term cultures
as cell lines. No significant effects of rhTNF or rhIL-1p on
3H-thymidine incorporation were noted after 24 h of culture.
After 72 h, no effects were seen in the HU xenograft in vitro
(data not shown). 3H-thymidine incorporation by the LA
xenograft was not affected by rhIL-l,, but was significantly
inhibited (P<0.005) at concentrations of rhTNF greater
than lOngml1l (Figure 3a). In contrast, rhTNF did not
inhibit 3H-thymidine incorporation by OS tumour cells, but
rhIL-1l3 markedly inhibited 3H-thymidine incorporation at
concentrations as low as 100 pg ml-' (Figure 3b).
Histological andpost-mortem studies
Post-mortem studies in HU and LA bearing mice treated
with diluent revealed free floating ascitic tumours at all times
from tumour injection to death (Figure 4a). However, i.p.
rhIL-1p injection led to marked macroscopic solid tumour
implantation in the peritoneal cavity in the HU and LA
Figure 2 Total peritoneal cell and neutrophil counts in tumour
bearing mice 24 h after injection of diluent (pbs), 1 jig rhIL-lp
(il-l), and 1 jg rhTNF (tnf). =1 = LA bearing mice. E = HU
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Figure 3 Effect of rhTNF (solid symbols) and rhIL-l,B (open
symbols) on 3H-thymidine incorporation by a, LA and b, OS
tumour cells in vitro.
xenograft models, with eradication of ascitic tumour. Histo-
logical examination revealed implantation of islands of viable
tumour cells in a well formed stromal reaction (Figure 4b)
that stained for collagen, laminin, and fibronectin. There was
no significant difference in the solid tumour burden in
rhTNF and rhIL-1p treated mice bearing the LA xenograft.
In HU bearing mice, rhIL-lp treated mice consistently show-
ed significantly greater solid tumour burdens compared to
rhTNF treated mice. In a typical experiment, diluent treated
mice had no measurable solid tumours at 7 and 14 days of
therapy. The corresponding solid tumour weights in rhIL-1p
and rhTNF treated mice (n = 4) were 1.23 ± 0.11 gm and
0.43 0.3 gm at 7 days (P<0.01), and 2.92 ± 0.6gm and
1.61 0.4 gm at 14 days (P<0.05) respectively. These
experiments all carried out with at least eight mice in each
group. TNF and IL-1lB were always compared in the same
experiment.
Solid tumours were found along the inner peritoneal wall













-o C'664 S.T.A. MALIK et al.
4
Figure 4 a, Peritoneal section from HU tumour bearing mouse treated with diluent showing free floating tumour cells (arrows) (x 500). b, Peritoneal section from HU tumour bearing mouse treated with rhIL-Ip for 7 days showing implantation of tumour cells (arrows) on the peritoneal surface (p) (x 500). c, OS tumour xenograft cells in the peritoneal lavage fluid of a mouse treated with rhTNF (1 jig day for 7 days) showing clumps of viable tumour cells (x 1,000). d, Necrotic OS tumour xenograft cells (arrows) in the peritoneal lavage fluid of a mouse treated with rhIL-lp (1 fig day for 7 days) ( x 1,000). e, Implants of OS tumour cells (T) on the diaphragm (d) of a mouse treated with rhIL-l1 (10 ng day for 3 weeks) (x 1,000). f, Implants of OS tumour cells (T) on the uterine surface of a mouse treated with rhIL-lp (10 ng day for 3 weeks). 0 = Ovary (x 200).
In OS mice treated with 1 jig day i.p. rhIL-1P, there was no
macroscopic evidence of tumour implantation or ascitic
tumour. Peritoneal lavage fluid cytospin preparations from
mice treated with rhTNF 7 days after commencement of
therapy, revealed viable tumour cells in rhTNF treated mice
(Figure 4c), whilst the tumour cells seen in the lavage fluid of
rhIL-lp treated mice showed marked degenerative changes as
early as 3 days after commencement of therapy (Figure 4d).
However, the presence of viable ascitic tumour was noted in
some mice that were treated with low dose of rhIL-l,B
(1-1Ongday) up to 20 days after start of therapy. At post-
mortem, microscopic peritoneal and diaphragmatic deposits
of tumour were seen in these mice (Figure 4e). Some mice
treated with doses of 10 ng day had survived up to 100 days
without outward signs of tumour, but at post mortem,
although there was no ascitic tumour, tumour implants were
visible in the peritoneal cavity. In one experiment, of the five
mice that were surviving with no outward signs of tumour up
to 100 days after treatment with 10 ng day rhIL-1,, four mice
had microscopic deposits of tumour on the diaphragms, and
two of these mice also had macroscopically visible deposits of
tumour on the uterus and ovaries (Figure 4f). These tumours
were well encapsulated, and occasionally showed areas of
dystrophic calcification. As with the other two xenografts, control mice always showed ascitic tumour at post mortem.
There was no evidence of solid tumour deposits.
IL-I induction by rhTNF
The release of IL-1 bioactivity in peritoneal lavage fluid with
time in OS tumour bearing mice after injection of I Ag rhTNF was assessed (Figure 5). A significant increase in IL-1
bioactivity was detected in peritoneal lavage fluid 60 min
after rhTNF injection, with peak activity at 90 min. The peak level of activity corresponded to a concentration of 70 pg ml-' of rhIL-1,. The IL-1 bioactivity declined thereafter, but
was still significantly higher at 24 h compared to baseline
values. No significant rise in IL-1 activity was noted after the
injection of rhTNF in non-tumour bearing mice. The IL-1
activity in peritoneal washes was not neutralised by anti-
human IL-1 antibodies, but was neutralised by antimurine
IL-1 antibody (data not shown).
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Figure 5 IL-1 activity in the peritoneal lavage fluid of mice at
various times after injection of 1 glg rhTNF. The absolute levels
of IL-1 were calculated from a standard curve in the NOB assay
obtained with rhIL-lp.
Northern analysis of tumour RNA confirmed that the
TNF induced IL-1 was of murine origin. None of the xeno-
grafts constitutively expressed human TNF or IL-1 mRNA.
Analysis of tumour mRNA from all three xenografts, at
times ranging from 30 min to 24 h after i.p. injection of
diluent or rhTNF did not reveal the induction of IL-1p (or
IL-lo) mRNA. RhTNF did lead to the induction of TNF
mRNA in the HU and OS xenografts, indicating that the
absence of IL-1 induction in tumour cells was not due to the
absence of TNF receptors on the tumour cells. The presence
of TNF receptors on LA tumour cells could be inferred from
the inhibition of 3H-thymidine incorporation by TNF in vitro
(Figure 3a).
The potential role of TNF induced IL-1 release in the HU
and LA xenograft models was studied by assessing tumour
implantation after 7 days of therapy. There was no evidence
of tumour implantation in any of the mice treated with i.p.
injection of rhIL-ll lower than lOOngday, suggesting that
physiological levels of IL-1 released after TNF injection did
not contribute to the TNF induced tumour implantation.
Conversely, there was no evidence that rhIL-lp led to the
induction of TNF mRNA in the human ovarian cancer
xenografts, or that injection of rhTNF at doses less than
lOOngday led to tumour implantation (Figure 6).
Discussion
This study has analysed the effects and interrelationships of
i.p. administration of rhIL-lp and rhTNF in three intra-
peritoneal human ovarian cancer xenograft models. RhIL-lp
was shown to cause peritoneal implantation and solid
tumour formation in two out of the three xenograft models
(HU and LA) at doses of 1 ig day. In a third xenograft
model (OS), rhIL-lp had a marked antitumour effect by
acting directly on the tumour cells. Although IL-1 has been
shown to inhibit the growth of ovarian cancer cell lines in
vitro (Killian et al., 1991), this is the first report showing the
in vivo antitumour effect of IL-1 in experimental ovarian
cancer. The antitumour effect was dose dependent, and lower
doses of rhIL-lp paradoxically led to tumour implantation in
this tumour model. The effects of recombinant rhIL-lp on
promoting the formation of micrometastases and solid
tumour implants in the peritoneal were similar to those of
rhTNF, but the antitumour effects were virtually the oppo-
site. Although both cytokines promoted solid tumour
implantation in the HU and LA xenografts, this appeared to
be accompanied, in the case of TNF by cytotoxic activity on
some of the tumour cell population. With IL-lp treatment,
the tumours were promoted to adhere to the peritoneal sur-
face but the eradication of tumour ascites was less complete
and there was no evidence of cytotoxicity of IL-1p for cells
from these two lines. This was reflected in the significantly
greater tumour burden seen in the IL-1p treated mice com-
pared to TNF treated mice in the HU treated mice.
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Figure 6 Northern analysis of xenograft RNA for human TNF
mRNA, human IL-1p mRNA, and P-actin. PMA stimulated HL
60 cells were used as positive controls. Tumour cells were col-
lected from HU and OS bearing mice (three per group) 4 h after
the injection of diluent (-), or I jig rhTNF (+).
Although PMNs have been implicated in the antitumour
effects of TNF and other i.p. therapies (Lichtenstein et al.,
1989; Shau, 1988), differences in peritoneal PMN influx could
not account for the differential effects of these cytokines in
the present study. In vitro studies showed that the marked
antitumour effect of rhIL-lp was due to a direct effect on OS
tumour cells. The differential cytotoxicity of TNF and rhIL-
1p for OS tumour cells are under investigation.
The mechanisms underlying the promotion of tumour
implantation by rhIL-lp and TNF in these models are likely
to be complex in view of the multiple cell regulatory effects
of these cytokines. Histological analysis of peritoneal
implants showed that there was marked generation of
tumour stroma which may enhance tumour implantation.
TNF and IL-1 have both been shown to have effects on
fibroblast proliferation and the generation of stroma
(Kovacs, 1990). A preliminary step to this may be the induc-
tion of increased adhesion of tumour cells to the peritoneal
mesothelium. Studies in this laboratory have shown that
TNF increased the adhesion of the ovarian cancer xenografts
to peritoneal explants in vitro (Malik, 1991), and it is likely
that IL-1 will have similar effects on tumour adhesion as
suggested by other investigators (Giavazzi et al., 1990; Bani
et al., 1991). There was a notable difference in the effects of
rhTNF and rhIL-lp on tumour implantation in the HU
xenograft model. RhIL-lp consistently led to the formation
of a greater solid tumour burden than that seen in TNF
treated mice. This may indicate an additional growth pro-
moting effect of rhIL-lp on this tumour xenograft in vivo.
TNF has been shown to induce IL-1 in several cell popula-
tions, e.g. monocytes, endothelial cells and fibroblasts (Philip
& Epstein, 1986; Elias et al., 1989). The present study
demonstrated that TNF induced IL-1 release from the
murine host, but not the human tumour cells. The most
probable cellular source of IL-1 in tumour bearing mice is
likely to be the peritoneal macrophage population. We were
unable to detect significant levels of IL-1 in peritoneal lavage
fluid from non-tumour bearing mice. Previous studies have
shown that the injection of the human ovarian cancer xeno-
grafts leads to a marked increase in the peritoneal macro-
phage population. However, although IL-1 release was
readily detectable in tumour bearing mice following injection
of rhTNF, similar doses of rhIL-1 did not reproduce the
effects of TNF in the HU and LA models. The low levels of
IL-1 released may have however contributed to tumour
implantation in the OS xenograft model.
There is increasing evidence of dysregulated cytokine bio-
logy in human ovarian cancer (Malik & Balkwill, 1991).
Previous studies have implicated endogenous TNF produc-
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tion in the pathophysiology of human ovarian cancer (Malik
et al., 1989; Malik et al., 1990; Naylor et al., 1990; Takeyama
et al., 1991; Dejaco et al., 1991). Some ovarian cancers have
been noted to express IL-1p mRNA and protein (unpublish-
ed data), and this cytokine may also contribute to the peri-
toneal spread of human ovarian cancer. However, it is also
possible that IL-1 may have significant antitumour activity
against some ovarian cancers, and the present study indicates
that it may be possible to identify these by testing the
sensitivity of these tumours to IL-1 in vitro.
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